Loading patent…
AssigneeTherabron Therapeutics, Inc.
InventorAprile L Clayton-Pilon
Estimating the term…
The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of Respiratory Distress Syndrome (RDS), Bronchopulmonary dysplasia (BPD), chronic lung disease and/or pulmonary fibrosis, Asthma and Chronic Obstructive Pulmonary Disease (COPD). More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.
A method for treatment of a patient having respiratory distress syndrome, bronchopulmonary dysplasia, chronic lung disease, pulmonary fibrosis, asthma or chronic obstructive pulmonary disease and in need of treatment, comprising:
A method for treatment of a patient having respiratory distress syndrome, bronchopulmonary dysplasia, chronic lung disease, pulmonary fibrosis, asthma or chronic obstructive pulmonary disease and in need of treatment, comprising the steps of:
A method for treatment of a premature infant having respiratory distress syndrome, bronchopulmonary dysplasia, asthma or chronic obstructive pulmonary disease and in need of treatment, comprising administering rhCC10 intratracheally to a premature infant at a dose of between about 0.15 mg/kg to about 5 mg/kg of patient body mass.
A method for treatment of a premature infant having respiratory distress syndrome, bronchopulmonary dysplasia, asthma or chronic obstructive pulmonary disease and in need of treatment, comprising administering rhCC10 intratracheally to a premature infant at a dose of between about 1.5 mg/kg to about 5 mg/kg of patient body mass.
A method for treatment of a premature infant having respiratory distress syndrome, bronchopulmonary dysplasia, asthma or chronic obstructive pulmonary disease and in need of treatment, comprising administering rhCC10 intratracheally to a premature infant at a dose of between about 1.5 mg/kg to about 5 mg/kg of patient body mass before, during, or after surfactant therapy.
A safe and well-tolerated method of treating at least one of respiratory distress syndrome, bronchopulmonary dysplasia, chronic lung disease, pulmonary fibrosis, asthma or chronic obstructive pulmonary disease in a patient comprising:
A safe and well-tolerated method of reducing total cell counts in the tracheal fluid of a patient comprising:
A safe and well-tolerated method of reducing total protein concentration in the tracheal fluid of a patient comprising:
Dependencies are inferred from the claim text.